Half dose of MydCombi achieves comparable short-term dilation as full dose
Click Here to Manage Email Alerts
INDIANAPOLIS — A single spray of MydCombi administered via the Optejet dispenser was comparable in efficacy to the label recommendation of two sprays in inducing clinically relevant mydriasis, according to researchers at Academy 2024.
“You can do a dilated internal exam on people with less waste, meaning drops are not running down the eye,” Denise Pensyl, OD, MS, study investigator and research optometrist at SUNY College of Optometry, told Healio. “The spray doesn’t waste as much of the drug, and potentially there is less of the drug to get into systemic absorption.”
To examine the safety and efficacy of a half dose, or one spray, of MydCombi (1% tropicamide and 2.5% phenylephrine ophthalmic solution, Eyenovia) using the Optejet dispenser (Eyenovia) for pupil dilation, Pensyl and colleagues conducted an open-label, phase 4 study of 58 eyes in 29 healthy adults (mean age, 36.4 years; men, n = 14).
Thirty minutes after dosing, 67% of eyes dilated to at least 6 mm, and 43% of eyes dilated to 7 mm, with 93% of participants returning to functional vision by 6 hours.
Study investigator Josianne Manasse, OD, a clinical research associate at SUNY College of Optometry, told Healio that these results demonstrate that a half dose was comparable in effectiveness to the full dose for short-term pupil dilation.
“The nice thing about this delivery system is that you don’t have to use an anesthetic,” Pensyl said, noting that this option could help reduce cost during dilated eye exams.
Collapse
Manasse J, et al. An open-label, phase 4 study of the safety and efficacy of fixed combination tropicamide 1% and phenylephrine 2.5% ophthalmic spray (MydCombi). Presented at: Academy 2024; Nov. 6-9, 2024; Indianapolis.
Read more about
Click Here to Manage Email Alerts